BARCELONA -- Rivaroxaban (Xarelto) appeared risky for treating atrial fibrillation in rheumatic heart disease, the INVICTUS trial showed. Rivaroxaban increased the composite of stroke, systemic ...

BARCELONA, Spain—(UPDATED) In patients with atrial fibrillation (AF) caused by rheumatic heart disease, a group excluded from contemporary stroke prevention trials of direct oral anticoagulants (DOACs ...

Adding the oral anticoagulant rivaroxaban (Xarelto, Janssen) to standard therapy after myocardial infarction (MI) or unstable angina significantly reduced the risk for cardiovascular mortality, data ...

The Food and Drug Administration approved the use of the blood thinner drug Xarelto to treat patients with atrial fibrillation, or irregular heartbeat, reports Reuters. Xarelto, first approved in 2011 ...

Lupin has received the Food and Drug Administration’s green light for rivaroxaban tablets, in 10 mg, 15 mg and 20 mg, which is the generic of Janssen’s Xarelto. This product will be manufactured at ...

The Food and Drug Administration has approved Bayer and J& J (NYSE: JNJ) drug Xarelto to treat atrial fibrillation, or abnormal heart rhythm. Earlier this year, Xarelto was approved for use as an anti ...

Bayer AG ((BAYRY)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

A win in patent court in Europe last October was a pleasant surprise for Bayer, giving its heart drug Xarelto an additional two years of exclusivity—all the way to 2026. But the generics ship already ...